Brown, Lisle/Cummings’s Editas Medicine EDIT Stock Holding History

Brown, Lisle/Cummings’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-65	Closed	-$222	–	644
2024 Q3	$222	Hold	65	–	–	﹤0.01%	612
2024 Q2	$304	Buy	+65	New	+$367	﹤0.01%	604

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown, Lisle/Cummings's EDIT Position: Q4 2024 in Review

Brown, Lisle/Cummings sold out of Editas Medicine (EDIT) in Q4 2024, closing a stake of 65 shares — an estimated $222 sold.

Brown, Lisle/Cummings first reported a position in EDIT in Q2 2024 and held it in 2 quarters. The position peaked at $304 in Q2 2024. 206 funds tracked by Wall St. Rank hold EDIT as of Q4 2024.

Brown, Lisle/Cummings reported no remaining Editas Medicine position as of Q4 2024 after selling out during the quarter.
Brown, Lisle/Cummings sold 65 Editas Medicine shares in Q4 2024, an estimated $222.
Brown, Lisle/Cummings first reported a position in Editas Medicine in Q2 2024 and held it in 2 quarters.
Brown, Lisle/Cummings's Editas Medicine position peaked at $304 in Q2 2024.
206 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2024.

Based on Brown, Lisle/Cummings's 13F filing for Q4 2024, filed 27 Jan 2025.